Side by side
Consultation participation and their own register declarations, side by side. Counts, not judgments — participation is not influence.
Counts here are a floor, never a total: they cover the 583 consultation files tracked so far (42,224 submissions, mostly 2025–26), so an organization's real filing history is larger, not smaller.
Company · Belgium
Declared costs: €200K+ a year · in the register since 2015
Industry association · Belgium
Declared costs: €1.5M+ a year · in the register since 2008
Medicinal products for human use · Revision of the EU legislation on medicines for children and rare diseases
Register facts self-declared (snapshot 2 Sept 2026); cost bands are floors. Shared files are shared attention, not evidence of coordination.
Their opening passages on the files they share, verbatim and in filing order. We do not summarize, compare, or characterize positions — read them at source.
UCB · filed 26 Apr 2021 · source
UCB has a fundamental commitment to enabling people living with severe diseases, their caregivers & families to live their best lives. We continuously innovate to bring differentiated solutions with unique outcomes, which help specific patients achieve their life goals. To deliver on that commitment now and into the future, sustainability is a strategic imperative for us.
American Chamber of Commerce to the EU · filed 27 Apr 2021 · source
The American Chamber of Commerce to the EU (AmCham EU) is committed to the development of a regulatory environment which furthers the capabilities of European healthcare, improving accessibility and ensuring a crisis-resistant medicines regulatory system.
American Chamber of Commerce to the EU · filed 6 Nov 2023 · source
Introduction To be truly future proof and innovation friendly, the EU's proposed pharmaceutical package must address the blocs declining attractiveness for investment. We therefore urge EU co-legislators to secure globally competitive incentives for research and development (R&D) and avoid additional unnecessary administrative burdens on companies.
American Chamber of Commerce to the EU · filed 6 Nov 2023 · source
Introduction To be truly future proof and innovation friendly, the EU's proposed pharmaceutical package must address the blocs declining attractiveness for investment. We therefore urge EU co-legislators to secure globally competitive incentives for research and development (R&D) and avoid additional unnecessary administrative burdens on companies.
UCB · filed 6 Jan 2021 · source
UCB is dedicated to finding unique solutions for diseases with high degree of patient need. Regardless of the population size, it’s patients’ needs that direct our efforts. Our ambition for patients relies on our ability to innovate & bring differentiated solutions with unique outcomes that help specific patients achieve their goals.
American Chamber of Commerce to the EU · filed 6 Jan 2021 · source
Representing American companies operating in the EU, AmCham EU is well aware of the differences and respective strengths of innovation ecosystems on both sides of the Atlantic. The options laid out in the inception impact assessment (IIA) risk undermining an EU framework that has proven largely successful, rather than preserving the EU’s strengths and incorporating learnings from other regions.
2 organizations on one sheet: every file each filed on, their register declarations, and a working link to each submission. Free: we ask for your name and email, and PolicySpeak may contact you about the product (privacy policy). The per-file record stays downloadable without signing up on each file’s page.